FUJIFILM Toyama Chemical Expands CDMO Services with Synplogen Partnership

• FUJIFILM Toyama Chemical and Synplogen announce a strategic business alliance to expand CDMO services for mRNA therapeutics.

• The alliance will provide seamless end-to-end services from mRNA sequence design to LNP formulation and fill/finish.

• The partnership aims to support the growth of the mRNA therapeutics market by integrating Synplogen’s expertise in mRNA sequence design and plasmid DNA synthesis.

FUJIFILM Toyama Chemical Co., Ltd and Synplogen Co., Ltd., a biotech startup company from Kobe University, have announced a strategic business alliance on Contract Development and Manufacturing Organisation (CDMO) services for mRNA therapeutics.

FUJIFILM Toyama Chemical has been providing one-stop-shop CDMO services from mRNA synthesis to lipid nanoparticle (LNP) formulation. This alliance with Synplogen expands its services to cover mRNA sequence design and synthesis of plasmid DNA, the starting material for mRNA production. “This provides seamless end-to-end services from mRNA sequence design to LNP formulation and fill/finish, ensuring consistent support throughout the drug discovery and development process,” said Mitsuhiro Sato, President of FUJIFILM Toyama Chemical.

Synplogen, established in February 2017, is a pioneering synthetic biology startup company from Graduate School of Science, Technology and Innovation, Kobe University. It is capable of synthesizing ultra-long and complex DNA and constructing DNA libraries with various combinations. Under this strategic alliance, Synplogen will provide mRNA sequence design and plasmid DNA synthesis services.

The emerging applications of mRNA therapeutics to infectious disease vaccines, cancer vaccines, and genetic disease therapeutics have led to an increase in the demand for contract manufacturing services. By integrating Synplogen’s expertise in mRNA sequence design and plasmid DNA synthesis with FUJIFILM Toyama Chemical’s current CDMO services, the companies aim to maximize their customer value for the mRNA therapeutics industry.

The strategic alliance between FUJIFILM Toyama Chemical and Synplogen is expected to support the growth of the mRNA therapeutics market, marking a significant step forward in the field of mRNA therapeutics. This partnership is a testament to the companies’ commitment to advancing healthcare and improving patient outcomes.